- Paricalcitol
Drugbox
IUPAC_name = (1"R",3"S")- 5-[2- [( 1R,3a"R",7a"S")-1-[ (2"R",5"S")-6-hydroxy-5,6-dimethyl-3"E"-hepten-2-yl] -
7a-methyl-2,3,3a,5,6,7-hexahydro-1"H"- inden-4-ylidene] ethylidene] -
cyclohexane-1,3-diol
CAS_number = 131918-61-1
CAS_supplemental =
ATC_prefix = A11
ATC_suffix = CC07
ATC_supplemental =
PubChem = 5281104
DrugBank =
chemical_formula =
C=27 | H=44 | O=3
molecular_weight = 416.636 g/mol
smiles =
bioavailability = N/A
protein_bound =
metabolism =
elimination_half-life =
excretion = Biliary
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = IntravenousParicalcitol (trade name Zemplar) is an analog of
calcitriol , the active form of vitamin D. It is used for the treatment ofsecondary hyperparathyroidism .Mechanism of action
Like calcitriol, paricalcitol acts as an agonist for the
calcitriol receptor and thus lowers the bloodparathormone level.A double-blind randomised study with 263 dialysis patients showed a significant advantage over calcitriol. After 18 weeks, all patients in the paricalcitol group had reached the target parathormone level of 100 to 300 pg/ml, versus none in the calcitriol group.
References
*Schubert-Zsilavecz, M, Wurglics, M, "Neue Arzneimittel 2005/2006".
Wikimedia Foundation. 2010.
